Generic Oncology Drugs Market Outlook (2022-2028)

[200 Pages Report] The worldwide generic oncology drugs market was valued at US$ 24.5 billion in 2022 and is predicted to increase at a 6% CAGR between 2022 and 2028, totalling more than US$ 34.8 billion by the end of 2028.

Rising generic oncology drugs sales are being attributed to:

  • Growing awareness of the benefits of generic oncology drugs, such as their low cost, is likely to drive the growth of the generic oncology drugs market over the forecast period.
  • Growing demand for specialty generics, as well as increased government efforts and funding, will generate possibilities for makers of generic oncology drugs in the future.
  • With cancer therapy expenses climbing and a growing demand for high-quality medical solutions, interest in generic oncology drugs has grown all across the world.

The corona virus pandemic had a significant influence on the global economy, creating several barriers for most businesses worldwide. However, due to increased utilisation for medication research, demand for generic cancer generic oncology drugs has increased dramatically. Generic oncology drugs are increasingly being repurposed due to their safety and efficacy in the treatment of a wide range of ailments affecting infected people.

The growing efforts of 18 key Indian industry actors, including Sun Pharma, Lupin, Aurobindo, and Zydus Cadila, to manufacture COVID-19 medications for developing nations boosted market demand. As per this report, demand for generic oncology drugs, is expected to surge at over 6% CAGR until 2028.

Attribute Details
Generic Oncology Drugs Market Size (2022) US$ 24.5 Billion
Generic Oncology Drugs Market Size (2028) US$ 34.8 Billion
Global Market Growth Rate (2022 to 2028) 6% CAGR
Market Share of Large Molecules 53.1%

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

Development of Generic Oncology Drugs Market in the North America

The United States now dominates the North American generic oncology drugs industry, which is predicted to increase rapidly between 2022 and 2028.

The rapid increase in cancer cases, growing adoption of branded generics, rising healthcare expenditure, high cancer diagnostic screening, availability of various innovative cancer treatments, and the large presence of leading generic drug manufacturers are driving growth in the U.S. generic oncology drugs market.

Multiple cancer cases have climbed significantly in recent years in the United States, and this trend is expected to continue even over the projected period. The American Cancer Society (ACS) predicts that there will be 1.9 million new cancer diagnoses and 609,360 cancer deaths in the United States in 2022. As a result, demand for generic oncology drugs is predicted to expand rapidly throughout the forecast period.

Similarly, rising R&D spending, quick expansion in the cancer supportive care products market, and an increase in new medication development and approvals would boost the country's generic oncology drug market share in the future years.

Generic Oncology Drugs Market

Opportunities abound in the Small Molecule Generic Oncology Drugs Segment

The worldwide generic oncology drugs market is divided into two segments based on molecule type: big molecule generic oncology drugs and small molecule generic oncology drugs. The big molecule generic oncology drugs sector now accounts for 53.1% of the worldwide generic oncology drugs market.

However, with increasing consumer preference for small molecule drugs due to their various benefits, the popularity of personalised drug development, and increased research and development activities, the small molecule generic oncology drugs segment is expected to grow at a higher CAGR during the forecast period.

Small molecule generic oncology drugs are increasing in popularity due to their improved safety, few side effects, and excellent treatment effectiveness. Because of their molecular size and complexity, they may quickly reach target areas. Similarly, the increase of the small-molecule injectable market will boost this segment's growth over the projection period.

A generic drug is a medication that contains the same chemical substance as a drug that was originally protected by chemical patents. It provides the same therapeutic effect as that of the original drug and is allowed for sale after the patents on the original drug expire.

The dramatic rise in cancer drug prices presents a tough challenge to treatment access and cancer outcomes. A large portion of the world population suffering from cancer is unable to afford proper cancer treatment due to staggering cancer treatment prices. As a result, they are continuously looking for low-cost cancer therapeutics. This has brought generic oncology drugs market into the spotlight.

Introduction of generic drugs in oncology has provided a new ray of hope to millions of patients suffering from various types of cancers, who cannot afford high-cost treatments. They have become ideal cost-effective alternatives to branded medicines and are being increasingly consumed by cancer patients worldwide.

Rise in cases of cancer coupled with growing awareness about the benefits of generic oncology drugs such as their cost effectiveness, is expected to provide a strong thrust to the growth of generic oncology drugs market during the forecast period.

Similarly, growing demand for specialty generics and increasing government initiatives and investments will create opportunities for generic oncology drugs manufacturers in future.

Currently, consumption of generic oncology drugs accounts for 17% share of the global oncology drugs market.

Sabyasachi Ghosh
Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

How The Market Progressed Till June 2022?

Particulars Details
H1, 2021 6.17%
H1, 2022 Projected 6.04%
H1, 2022 Outlook 5.14%
BPS Change - H1, 2022 (O) – H1, 2022 (P) (-) 90 ↓
BPS Change – H1, 2022 (O) – H1, 2021 (-) 103 ↓

According to Future Market Insights' analysis, the global generic oncology drugs market expects to drop by 103 Basis Point Share (BPS) in H1-2022 as compared to H1- 2021. Whereas in comparison to H1-2022 Projected value, the market during H1-2022 outlook period will show a dip of 90 BPS.

The resultant decline in the BPS values is associated with the existing international variability in the safety of generic oncology drugs, thus posing regulatory along with patient safety concerns. Moreover, drawbacks in generic pharmaceuticals production in developing countries such as India, due to a less intensive regulatory oversight has further deteriorated the BPS value change.

The market will however observe a positive growth outlook, owed to the significantly improved cost-effectiveness and cost–utility offered by the generic versions of costly oncology drugs in the developed countries.

The market is subject to changes as per the clinical, policy, regulatory and patient safety factors, in accordance to the macroeconomic and industry standards. The key development in the market includes the launch of the cancer drug Ibrance, for targeted therapy.

Demand Analysis Of Generic Oncology Drugs (2013 To 2021) Vs Industry Outlook (2022 To 2028)

The global demand for generic oncology drugs is set to grow at a healthy CAGR of 6.0% between 2022 and 2028, in comparison to 5.8% CAGR registered from 2014 to 2021. Growth in the generic oncology drugs market is driven by rising incidence of cancer, growing awareness among people about cancer and its treatments, cost effective nature of generic oncology drugs, favorable government support, and rise in new generic oncology drug launches and approvals.

With skyrocketing costs of cancer therapeutics and rising need for quality medical options, the interest in generics oncology drugs has increased all over the world. Generic oncology drugs are a chemical copy of original band, with the same active ingredients.

These drugs tend to cost less than their brand-name counterparts because generic drug applicants do not have to repeat the costly clinical trials. Generic drugs in oncology have become essential because some anticancer drugs are only available as generics.

Increasing incidence of cancer is a major factor boosting the growth of generic oncology drugs market and the trend is likely to continue during the forecast period. According to the World Health Organization (WHO), with around 10 million deaths in 2020, cancer was the leading cause of death worldwide.

In order to reduce this mortality rate, people opt for various cancer treatments including generic oncology drugs. This surge in numerous types of cancers such as breast cancer and lung cancer will continue to boost the sale of generic oncology drugs like breast cancer drugs and lung cancer therapeutics, thereby improving the generic oncology drugs market share.

Similarly, growing popularity of generic oncology drugs due to their cost-effective nature along with growing popularity of super generics is expected to boost the generic oncology drugs market growth during the forecast period. Generic oncology drugs are usually priced at affordable rates with costs that are up to 80% less than branded drugs. As a result, people are showing a keen inclination towards using these generic oncology drugs.

Leading generic oncology drugs manufacturers are frequently launching new products in order to meet the rising demand. This will ignite the growth of generic oncology medicines market during the forecast period.

Get the data you need at a Fraction of the cost

Personalize your report by choosing insights you need
and save 40%!

Which Factors Are Restraining The Growth Of Generic Oncology Drugs Market?

“Oncologists’ Scepticism on Effectiveness Could Hinder Generic Oncology Drug Sales”

Despite its optimistic stance, the global generic oncology drugs market is facing various challenges that are restraining its growth to some extent. Some of these factors include scepticism about the effectiveness of generic oncology drugs, longer approvals time, and increasing usage of alternative cancer treatments.

Country-Wise Analysis

What is the Demand Outlook for the India Generic Oncology Drugs Market?

“Rapid Rise in the Export of Generic Medicines and Growing Demand for Affordable Cancer Treatments Propelling Sales of Generic Oncology Drugs in India”

As per FMI, the generic oncology drugs market in India is expected to grow at a healthy pace during the forecast period, owing to the rapid surge in cancer cases, rising adoption of cancer diagnostic technologies like oncology blood testing, growing health awareness, rise in export of medicines, and increasing demand for low-cost medicines.

Over the years, India has become one of the biggest exporters of generic medicines to several developed countries including the U.S., Russia, and the U.K. Africa. According to the India Brand Equity Foundation (IBEF), the country (India) exported pharma products worth US$ 24.62 billion during 2021 –2022.

Factors such as easy availability of labors, low cost of manufacturing, and supportive government initiatives are attracting generic oncology drug manufacturers to establish their bases in India. This will bode well for the India Generic oncology drugs market during the forecast period.

Indian based pharmaceutical giants like Dr. Reedy's Laboratories and Aurobindo Pharma, are playing a key role in expanding the generic oncology drugs market size in the country. These generic oncology drugs manufacturers are developing novel generic drugs to penetrate attractive markets. For instance, in October 2021, DR Reddy's Laboratories launched its anti-cancer drug, Abiraterone Acetate in Chinese market.

How Will Growth Unfold in the U.S. Generic Oncology Drugs Market?

“Rising Incidence of Cancer and Increase in Generic Drug Launches and Approvals Spurring Growth of Generic Oncology Drugs Market in the U.S.”

The U.S. currently leads the North American generic oncology drugs market and is expected to grow at a considerable pace during the forecast period between 2022 and 2032.

Growth in the U.S. generic oncology drugs market is driven by rapid surge in cancer cases, growing adoption of branded generics, increasing healthcare expenditure, high cancer diagnostic screening, availability of various innovative cancer treatments, and large presence of leading generic drug manufacturers.

In recent years instances of multiple cancers have increased substantially in the U.S. and this trend is anticipated to continue even during the forecast period. According to the American Cancer Society (ACS), there will be an estimated 1.9 million new cancer cases and 609,360 cancer deaths in the United States during 2022. Driven by this, demand for generic oncology drugs is expected to rise at a robust pace during the forecast period.

Similarly, increasing investments in research and development, rapid growth of cancer supportive care products market, and rise in new drug development and approvals will improve the generic oncology drugs market share in the country during the forthcoming years.

Category-Wise Analysis

Which Molecule Type Segment Will Contribute Most to the Generic Oncology Drugs Market?

“Demand for Small Molecule Generic Oncology Drugs to Grow at an Exponential Pace”

Based on molecule type, the global generic oncology drugs market is segmented into large molecule generic oncology drugs and small molecule generic oncology drugs. Among these two, large molecule generic oncology drugs segment currently holds the largest share of 53.1% of the global generic oncology drugs market.

However, with growing consumer preference for small molecule drugs due to their various benefits, growing popularity of personalized drug development, and increasing research and development activities, the small molecule generic oncology drugs segment is expected to grow at a relatively higher CAGR during the forecast period.

Small molecule generic oncology drugs are gradually gaining popularity on account of their enhanced safety, minimal side effects, and high drug efficacy. Their molecular size and complexity enable them to reach target sites easily.

Similarly, expansion of small-molecule injectable market will further support the growth of this segment during the forecast period.

Which Distribution Channel Dominates the Global generic oncology drugs market?

“Online Pharmacies to Remain the Mostly Preferred Distribution Channel for Generic Oncology Drugs”

Emerging generic oncology market trends indicate that the online pharmacies segment is likely to grow at the highest CAGR during the forecast period. This can be attributed to rising consumer inclination towards purchasing generic oncology drugs from their homes to save money and time and rise in the number of online pharmacies worldwide. Further, online pharmacies also render higher interoperability in comparison to the hospital systems.

Who Are The Top Players In Generic Oncology Drugs Market?

Some of the leading players in generic oncology drugs market include Novartis AG, CELGENE CORPORATION, Merck & Company Inc., Pfizer Inc., GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd., NATCO Pharma Limited, Aurobindo Pharma, Hikma Pharmaceuticals PLC, and Mylan N.V. They are committed to discovering, investigating, and developing transformative therapies that improve the outlook for cancer patients worldwide.

These leading generic oncology drugs manufacturers are increasingly investing in research and development for introducing novel oncology drugs with better effectiveness and low costs.

Besides this, they have adopted strategies like new product launches and approvals, partnerships, collaborations, acquisitions, mergers, and strengthening of distribution channels to gain a competitive edge in the global generic oncology drugs market.

For instance,

  • In February 2021, Glenmark Pharmaceuticals, a research-led, global integrated pharmaceutical company, launched SUTIB, the generic version of Sunitinib oral capsules to treat kidney cancer in India. The new generic drug is priced 96% lower than the innovator brand to make it affordable to maximum patients.
  • In February 2022, Sandoz, a pharmaceutical company headquartered in Switzerland, launched generic oncology medicine lenalidomide in 19 countries across Europe to provide patients access to affordable, high-quality medicines.
  • In June 2022, NATCO Pharma Limited announced the launch of the first generic version of Nexavar (Sorafenib) tablets in the U.S. market.

Key Segments Of Generic Oncology Drugs Industry Survey

Generic Oncology Drugs Market by Molecule Type:

  • Large Molecule Generic Oncology Drugs
  • Small Molecule Generic Oncology Drugs

Generic Oncology Drugs Market by Route of Administration:

  • Oral Generic Oncology Drugs
  • Parenteral Generic Oncology Drugs

Generic Oncology Drugs Market by Distribution Channel:

  • Generic Oncology Drugs Sold at Hospital Pharmacies
  • Generic Oncology Drugs Sold at Retail Pharmacies
  • Generic Oncology Drugs Sold at Online Pharmacies
  • Generic Oncology Drugs Sold at Managed Care Institutions

Generic Oncology Drugs Market by Region:

  • North America Generic Oncology Drugs Market
  • Latin America Generic Oncology Drugs Market
  • Europe Generic Oncology Drugs Market
  • East Asia Generic Oncology Drugs Market
  • South Asia & Pacific Generic Oncology Drugs Market
  • Middle East & Africa (MEA) Generic Oncology Drugs Market

Generic Oncology Drugs Market Scope

With the aim of providing a detailed analysis of the global generic oncology drugs market, Future Market Insights latest report delves deep into various market governing factors such as growth drivers, restraints, consumer demands, emerging generic oncology drugs market trends. It offers insights into leading regional pockets and market segments.

The report also provides in-depth analysis regarding the competitive landscape of generic oncology drugs market and explains how key generic oncology drugs manufacturers are innovating to meet consumer demands.

Besides this, FMI also examines the impact of rising cancer cases and advancing cancer diagnostic technologies on the overall sales of generic oncology drugs. The report further highlights factors pushing demand for generic oncology drugs across developing regions like India and China.

The Generic Oncology Drugs Market Analysis Includes:

  • A 6-year realistic sales forecast of generic oncology drugs across multiple end use verticals
  • Key market dynamics including drivers, restraints, and emerging opportunities
  • Generic oncology drugs market segmentation and information about leading segments
  • Insights into latest generic oncology drugs market trends
  • Details of leading generic oncology drugs manufacturers and their respective growth strategies to penetrate attractive markets
  • Opportunity assessment
  • The winning imperatives in generic oncology drugs market
  • Supply chain analysis
  • Pricing analysis
Attribute Details
Projected Market Size (2028) US$ 34.8 Billion
Estimated Growth Rate (2022-2028) 6%
Forecast Period 2022 to 2028
Historic Data Available for 2013 to 2021
Market Analysis USD Million for Value
Report Coverage Market forecast, company share analysis, competition intelligence, DROT analysis, market dynamics and challenges, and strategic growth initiatives
Key Segments Covered
  • Molecule Type
  • Route of Administration
  • Distribution Channel
  • Region
Key regions covered North America
  • USA
  • Canada
  • Rest of North America
Latin America
  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America
Western Europe
  • Germany
  • UK
  • France
  • Rest of Western Europe
Eastern Europe
  • Russia
  • Spain
  • Rest of Eastern Europe
South Asia Pacific
  • China
  • India
  • Japan
  • Malaysia
  • Thailand
  • Indonesia
  • South Korea
  • Rest of South Asia & Pacific
Middle East & Africa
  • GCC Countries
  • Turkey
  • Israel
  • Rest of MEA
Rest of the World
  • Oceania
  • Africa
  • South America
Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Managed Care Institutions
Key companies profiled Novartis AG, CELGENE CORPORATION, Merck & Company Inc., Pfizer Inc., GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd., NATCO Pharma Limited, Aurobindo Pharma, Hikma Pharmaceuticals PLC, and Mylan N.V.
Customization & pricing Available upon request

Frequently Asked Questions

What is the current valuation of the global generic oncology drugs market?

The global generic oncology drugs market reached a valuation of US$ 24.5 Bn in 2022.

What is the demand outlook for generic oncology drugs market?

Demand for generic oncology drugs is expected to rise at 6% CAGR during the forecast period, totaling US$ 34.8 Bn by 2028.

Which molecule type segment leads the generic oncology drugs market?

Currently, large molecule generic oncology drugs segment leads the market with around 53.1% share.

Which factors are shaping the growth of generic oncology drugs market?

Increasing prevalence of cancer, growing awareness about cancer and its various treatments, and continuous new product launches are some of the key factors shaping the growth of generic oncology drugs market.

Who are some of the prominent players operating in generic oncology drugs market?

Novartis AG, GlaxoSmithKline plc, CELGENE CORPORATION, Pfizer Inc., Teva Pharmaceutical Industries Ltd., Aurobindo Pharma, and Merck & Company Inc. are some of the prominent players operating in generic oncology drugs market.

Table of Content
1. Executive Summary
     1.1. Market Overview
     1.2. Market Analysis
     1.3. FMI Analysis and Recommendations
     1.4. Wheel of Fortune
2. Market Introduction
     2.1. Market Taxonomy
     2.2. Market Definition
3. Market Opportunity Analysis 
     3.1. Macro-Economic Factors
     3.2. Opportunity Analysis
4. Market Background
     4.1. PESTLE Analysis
     4.2. Market Dynamics
            4.2.1. Drivers
            4.2.2. Restraints
            4.2.3. Trends
     4.3. Regulatory Scenario
5. Key Inclusions
     5.1. Pipeline
6. North America Market Analysis 2013–2021 and Forecast 2022–2028
     6.1. Introduction
     6.2. Historical Market Size (US$ Mn) Analysis By Country, 2013-2021
            6.2.1. U.S.
            6.2.2. Canada
     6.3. Market Size (US$ Mn) Forecast By Country, 2022-2028
     6.4. Historical Market Size (US$ Mn) Trend Analysis By Molecule Type, 2013-2021
            6.4.1. Large Molecule
            6.4.2. Small Molecule
     6.5. Market Size (US$ Mn) Forecast By Molecule Type, 2022-2028
     6.6. Historical Market Size (US$ Mn) Trend Analysis By Route of Administration, 2013-2021
            6.6.1. Oral
            6.6.2. Parenteral
     6.7. Market Size (US$ Mn) Forecast By Route of Administration, 2022-2028
     6.8. Historical Market Size (US$ Mn) Trend Analysis By Distribution Channel, 2013-2021
            6.8.1. Hospital Pharmacy
            6.8.2. Retail Pharmacy
            6.8.3. Online Pharmacy
            6.8.4. Managed Care Institutions
     6.9. Market Size (US$ Mn) Forecast By Distribution Channel, 2022-2028
     6.10. Drivers and Restraints: Impact Analysis
     6.11. Market Attractiveness Analysis
            6.11.1. By Country
            6.11.2. By Molecule Type
            6.11.3. By Route of Administration
            6.11.4. By Distribution Channel
7. Western Europe Market Analysis 2013–2021 and Forecast 2022–2028
     7.1. Introduction
     7.2. Historical Market Size (US$ Mn) Analysis By Country, 2013-2021
            7.2.1. Germany
            7.2.2. U.K
            7.2.3. France
            7.2.4. Italy
            7.2.5. Spain
            7.2.6. Rest of Western Europe
     7.3. Market Size (US$ Mn) Forecast By Country, 2022-2028
     7.4. Historical Market Size (US$ Mn) Trend Analysis By Molecule Type, 2013-2021
            7.4.1. Large Molecule
            7.4.2. Small Molecule
     7.5. Market Size (US$ Mn) Forecast By Molecule Type, 2022-2028
     7.6. Historical Market Size (US$ Mn) Trend Analysis By Route of Administration, 2013-2021
            7.6.1. Oral
            7.6.2. Parenteral
     7.7. Market Size (US$ Mn) Forecast By Route of Administration, 2022-2028
     7.8. Historical Market Size (US$ Mn) Trend Analysis By Distribution Channel, 2013-2021
            7.8.1. Hospital Pharmacy
            7.8.2. Retail Pharmacy
            7.8.3. Online Pharmacy
            7.8.4. Managed Care Institutions
     7.9. Market Size (US$ Mn) Forecast By Distribution Channel, 2022-2028
     7.10. Drivers and Restraints: Impact Analysis
     7.11. Market Attractiveness Analysis
            7.11.1. By Country
            7.11.2. By Molecule Type
            7.11.3. By Route of Administration
            7.11.4. By Distribution Channel
8. Eastern Europe Market Analysis 2013–2021 and Forecast 2022–2028
     8.1. Introduction
     8.2. Historical Market Size (US$ Mn) Analysis By Country, 2013-2021
            8.2.1. Russia
            8.2.2. Poland
            8.2.3. Rest of Eastern Europe
     8.3. Market Size (US$ Mn) Forecast By Country, 2022-2028
     8.4. Historical Market Size (US$ Mn) Trend Analysis By Molecule Type, 2013-2021
            8.4.1. Large Molecule
            8.4.2. Small Molecule
     8.5. Market Size (US$ Mn) Forecast By Molecule Type, 2022-2028
     8.6. Historical Market Size (US$ Mn) Trend Analysis By Route of Administration, 2013-2021
            8.6.1. Oral
            8.6.2. Parenteral
     8.7. Market Size (US$ Mn) Forecast By Route of Administration, 2022-2028
     8.8. Historical Market Size (US$ Mn) Trend Analysis By Distribution Channel, 2013-2021
            8.8.1. Hospital Pharmacy
            8.8.2. Retail Pharmacy
            8.8.3. Online Pharmacy
            8.8.4. Managed Care Institutions
     8.9. Market Size (US$ Mn) Forecast By Distribution Channel, 2022-2028
     8.10. Drivers and Restraints: Impact Analysis
     8.11. Market Attractiveness Analysis
            8.11.1. By Country
            8.11.2. By Molecule Type
            8.11.3. By Route of Administration
            8.11.4. By Distribution Channel
9. Latin America Market Analysis 2013–2021 and Forecast 2022–2028
     9.1. Introduction
     9.2. Historical Market Size (US$ Mn) Analysis By Country, 2013-2021
            9.2.1. Brazil
            9.2.2. Mexico
            9.2.3. Rest of Latin America
     9.3. Market Size (US$ Mn) Forecast By Country, 2022-2028
     9.4. Historical Market Size (US$ Mn) Trend Analysis By Molecule Type, 2013-2021
            9.4.1. Large Molecule
            9.4.2. Small Molecule
     9.5. Market Size (US$ Mn) Forecast By Molecule Type, 2022-2028
     9.6. Historical Market Size (US$ Mn) Trend Analysis By Route of Administration, 2013-2021
            9.6.1. Oral
            9.6.2. Parenteral
     9.7. Market Size (US$ Mn) Forecast By Route of Administration, 2022-2028
     9.8. Historical Market Size (US$ Mn) Trend Analysis By Distribution Channel, 2013-2021
            9.8.1. Hospital Pharmacy
            9.8.2. Retail Pharmacy
            9.8.3. Online Pharmacy
            9.8.4. Managed Care Institutions
     9.9. Market Size (US$ Mn) Forecast By Distribution Channel, 2022-2028
     9.10. Drivers and Restraints: Impact Analysis
     9.11. Market Attractiveness Analysis
            9.11.1. By Country
            9.11.2. By Molecule Type
            9.11.3. By Route of Administration
            9.11.4. By Distribution Channel
10. Asia Pacific Excluding China & Japan Market Analysis 2013–2021 and Forecast 2022–2028
     10.1. Introduction
     10.2. Historical Market Size (US$ Mn) Analysis By Country, 2013-2021
            10.2.1. India
            10.2.2. Australia and New Zealand
            10.2.3. ASEAN
            10.2.4. Rest of APECJ
     10.3. Market Size (US$ Mn) Forecast By Country, 2022-2028
     10.4.Historical Market Size (US$ Mn) Trend Analysis By Molecule Type, 2013-2021
            10.4.1. Large Molecule
            10.4.2. Small Molecule
     10.5. Market Size (US$ Mn) Forecast By Molecule Type, 2022-2028
     10.6.Historical Market Size (US$ Mn) Trend Analysis By Route of Administration, 2013-2021
            10.6.1. Oral
            10.6.2. Parenteral
     10.7.Market Size (US$ Mn) Forecast By Route of Administration, 2022-2028
     10.8.Historical Market Size (US$ Mn) Trend Analysis By Distribution Channel, 2013-2021
            10.8.1. Hospital Pharmacy
            10.8.2. Retail Pharmacy
            10.8.3. Online Pharmacy
            10.8.4. Managed Care Institutions
     10.9.Market Size (US$ Mn) Forecast By Distribution Channel, 2022-2028
     10.10. Drivers and Restraints: Impact Analysis
     10.11. Market Attractiveness Analysis
            10.11.1. By Country
            10.11.2. By Molecule Type
            10.11.3. By Route of Administration
            10.11.4. By Distribution Channel
11. China Market Analysis 2013–2021 and Forecast 2022–2028
     11.1. Introduction
     11.2.Historical Market Size (US$ Mn) Trend Analysis By Molecule Type, 2013-2021
            11.2.1. Large Molecule
            11.2.2. Small Molecule
     11.3. Market Size (US$ Mn) Forecast By Molecule Type, 2022-2028
     11.4.Historical Market Size (US$ Mn) Trend Analysis By Route of Administration, 2013-2021
            11.4.1. Oral
            11.4.2. Parenteral
     11.5.Market Size (US$ Mn) Forecast By Route of Administration, 2022-2028
     11.6.Historical Market Size (US$ Mn) Trend Analysis By Distribution Channel, 2013-2021
            11.6.1. Hospital Pharmacy
            11.6.2. Retail Pharmacy
            11.6.3. Online Pharmacy
            11.6.4. Managed Care Institutions
     11.7. Market Size (US$ Mn) Forecast By Distribution Channel, 2022-2028
     11.8. Drivers and Restraints: Impact Analysis
     11.9. Market Attractiveness Analysis
            11.9.1. By Molecule Type
            11.9.2. By Route of Administration
            11.9.3. By Distribution Channel
12. Japan Market Analysis 2013–2021 and Forecast 2022–2028
     12.1. Introduction
     12.2.Historical Market Size (US$ Mn) Trend Analysis By Molecule Type, 2013-2021
            12.2.1. Large Molecule
            12.2.2. Small Molecule
     12.3. Market Size (US$ Mn) Forecast By Molecule Type, 2022-2028
     12.4.Historical Market Size (US$ Mn) Trend Analysis By Route of Administration, 2013-2021
            12.4.1. Oral
            12.4.2. Parenteral
     12.5. Market Size (US$ Mn) Forecast By Route of Administration, 2022-2028
     12.6. Historical Market Size (US$ Mn) Trend Analysis By Distribution Channel, 2013-2021
            12.6.1. Hospital Pharmacy
            12.6.2. Retail Pharmacy
            12.6.3. Online Pharmacy
            12.6.4. Managed Care Institutions
     12.7. Market Size (US$ Mn) Forecast By Distribution Channel, 2022-2028
     12.8. Drivers and Restraints: Impact Analysis
     12.9. Market Attractiveness Analysis
            12.9.1. By Molecule Type
            12.9.2. By Route of Administration
            12.9.3. By Distribution Channel
13. Middle East and Africa Market Analysis 2013–2021 and Forecast 2022–2028
     13.1. Introduction
     13.2. Historical Market Size (US$ Mn) Analysis By Country, 2013-2021
            13.2.1. GCC Countries
            13.2.2. South Africa
            13.2.3. Rest of Middle East and Africa
     13.3. Market Size (US$ Mn) Forecast By Country, 2022-2028
     13.4. Historical Market Size (US$ Mn) Trend Analysis By Molecule Type, 2013-2021
            13.4.1. Large Molecule
            13.4.2. Small Molecule
     13.5. Market Size (US$ Mn) Forecast By Molecule Type, 2022-2028
     13.6.Historical Market Size (US$ Mn) Trend Analysis By Route of Administration, 2013-2021
            13.6.1. Oral
            13.6.2. Parenteral
     13.7. Market Size (US$ Mn) Forecast By Route of Administration, 2022-2028
     13.8. Historical Market Size (US$ Mn) Trend Analysis By Distribution Channel, 2013-2021
            13.8.1. Hospital Pharmacy
            13.8.2. Retail Pharmacy
            13.8.3. Online Pharmacy
            13.8.4. Managed Care Institutions
     13.9. Market Size (US$ Mn) Forecast By Distribution Channel, 2022-2028
     13.10. Drivers and Restraints: Impact Analysis
     13.11. Market Attractiveness Analysis
            13.11.1. By Country
            13.11.2. By Molecule Type
            13.11.3. By Route of Administration
            13.8.4. By Distribution Channel
14. Forecast Factors: Relevance and Impact
15. Forecast Assumptions
16. Competition Analysis
     16.1.Competition Dashboard
     16.2.Company Deep Dive
            16.2.1. Novartis AG
                      16.2.1.1. Overview
                      16.2.1.2. Treatment and Application Portfolio
                      16.2.1.3. Product Footprint
                      16.2.1.4. Sales Footprint
                      16.2.1.5. Channel Footprint
                      16.2.1.6. Strategy
                                 16.2.1.6.1.1 Marketing Strategy
                                 16.2.1.6.1.2. Treatment Strategy
                                 16.2.1.6.1.3. Channel Strategy
            16.2.2. Pfizer Inc.
            16.2.3. GlaxoSmithKline plc
            16.2.4. CELGENE CORPORATION
            16.2.5. Teva Pharmaceutical Industries Ltd.
            16.2.6. Merck & Company, Inc
            16.2.7. Aurobindo Pharma.
            16.2.8. Hikma Pharmaceuticals PLC 
            16.2.9. Mylan N.V.
            16.2.10. NATCO Pharma Limited.
17. Global Market Analysis 2013–2021 and Forecast 2022–2028 By Region
     17.1. Introduction / Key Findings
     17.2. Historical Market Size (US$ Mn) Analysis By Region
            17.2.1. North America
            17.2.2. Western Europe
            17.2.3. Eastern Europe
            17.2.4. Latin America
            17.2.5. Asia Pacific Excluding Japan
            17.2.6. Japan
            17.2.7. China
            17.2.8. Middle East and Africa
     17.3. Market Size (US$ Mn) Forecast By Region
     17.4. Market Attractiveness Analysis By Region
18. Global Market Analysis 2013–2021 and Forecast 2022–2028, By Molecule Type
     18.1. Introduction/Key Finding
     18.2. Historical Market Size (US$ Mn) Trend Analysis By Molecule Type, 2013-2021
            18.2.1. Large Molecule
            18.2.2. Small Molecule
     18.3.Market Size (US$ Mn) Forecast By Molecule Type, 2022-2028
     18.4. Market Attractiveness Analysis By Molecule Type
19. Global Market Analysis 2013–2021 and Forecast 2022–2028, By Route Of Administration
     19.1.Introduction/Key Finding
     19.2. Historical Market Size (US$ Mn) Trend Analysis By Route Of Administration, 2013-2021
            19.2.1. Oral
            19.2.2. Parenteral
     19.3.Market Size (US$ Mn) Forecast By Route Of Administration, 2022-2028
     19.4.Market Attractiveness Analysis By Route Of Administration
20. Global Market Analysis 2013–2021 and Forecast 2022–2028, By Distribution Channel
     20.1.Introduction/Key Finding
     20.2. Historical Market Size (US$ Mn) Trend Analysis By Distribution Channel, 2013-2021
            20.2.1. Hospital Pharmacy
            20.2.2. Retail Pharmacy
            20.2.3. Online Pharmacy
            20.2.4. Managed Care Institutions
     20.3.Market Size (US$ Mn) Forecast By Distribution Channel, 2022-2028
     20.4.Market Attractiveness Analysis By Distribution Channel
21. Global Market Analysis 2013–2021 and Forecast 2022–2028
     21.1.Market Value Share Analysis By All Segment
     21.2.Y-o-Y Growth Analysis By All Segment
     21.3.Absolute $ Opportunity
22. Assumptions and Acronyms Used
23. Research Methodology
Recommendations

Healthcare

Orthopedic Oncology Market

June 2023

REP-GB-1523

243 pages

Healthcare

Musculoskeletal Oncology Therapeutics Market

December 2024

REP-GB-1572

Upcoming

Explore Healthcare Insights

View Reports
Future Market Insights

Generic Oncology Drugs Market

Schedule a Call